GPX3 and prostate carcinoma: Research indicates that the dysfunction of GPX3 expression in tumor cells is linked to a poor prognosis for patients with cancer and chemotherapeutic resistance 44, including endometrial adenocarcinoma 45, lung cancer 46, gastric cancer 47, prostate cancer 48, cervical cancer 49, and thyroid cancer 50.